Bibliography
- Cahn P, Cassetti I, Wood R, et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 2006;20:1261-8
- Cahn P, Altclas J, Martins M, et al. Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected patients failing therapy with M184V and NRTI resistance [abstract WESS203]. Oral presentation at 4th IAS conference on HIV Pathogenesis, Treatment and Prevention; 22 – 25 July 2007; Sydney, Australia
- Bethell RC, Lie YS, Parkin NT. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir Chem Chemother 2005;16:295-302
- Gu Z, Allard B, de Muys JM, et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50:625-31
- Sawyer J, Struthers-Semple C. Pharmacokinetics of apricitabine in healthy volunteers and HIV infected individuals [abstract TUPE0077]. XVI International AIDS Conference; 13 – 18 August 2006; Toronto, Canada
- De Muys JM, Gourdeau H, Nguyen-Ba N, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob Agents Chemother 1999;43:1835-44
- Low A, Markowitz M. Predictors of response to highly active antiretroviral therapy. AIDS Read 2006;16:425-8, 430-1, 434, 436
- Smith RJ. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? Proc Biol Sci 2006;273:617-24
- Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007;186:146-51
- Holdich T, Shiveley L, Sawyer J. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers. Clin Drug Investig 2006;26:279-86
- Forrest A, Smith P, Sawyer J, et al. Study 754-101: single dose pharmacokinetics (pk) of SPD754 in healthy adult volunteers [abstract A-1046]. Proceedings and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC: American Society for Microbiology; 2002. p. 23
- Francis RJ, Lanclos L, Shiveley L, Sawyer J. Pharmacokinetics (PK) of SPD754, a new cytidine analogue, in healthy volunteers [abstract 528]. Antiviral Ther 2003;8(Suppl 1):S325